Better Therapeutics to Present Health Economic Data at ISPOR 2019

Share Article

Research estimates cost savings of 30-40% over traditional treatments using Better’s digital behavioral intervention in type 2 diabetes and hypertension

Better Therapeutics, a developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, today announced an upcoming poster presentation of health economic data at the ISPOR 2019 Conference May 18 - 22 in New Orleans. The presentation will include data on the reduction of health resource utilization and cost-effectiveness of Better’s digital behavioral intervention in type 2 diabetes and hypertension.

Recognizing there are few existing assessments of the economic benefits of digital therapeutics, Better commissioned health economic and outcomes research (HEOR) to understand the cost-effectiveness of its intervention by analysing both economic and clinical benefit. The poster presentation will present selected data from that research.

Here are the details of the upcoming poster presentation:

Poster Title: Estimating the economic impact of novel digital therapeutics in type 2 diabetes and hypertension
Poster Location: B9
Date & Time: Wednesday, May 22nd, 9:30 am - 2:00 pm

Abstracts will be published following the conference as a supplement to Value in Health, the journal of The International Society for Pharmacoeconomics and Outcomes Research, and on the Better Therapeutics website. Complete data are undergoing peer-review and will be published later this year.

Highlights of the research include:

  • Cost savings are estimated to be 30-40% of the average annual cost of conventional treatments
  • Clinical inertia - the resistance to reducing use of prescription drugs, may be important in realizing the full benefits of digital therapeutics
  • Average estimated savings over 3-years ranged from $96 to $145 per participant per month, with higher potential benefits in type 2 diabetes

About Better Therapeutics
Better develops prescription software for treating cardiometabolic diseases. By integrating elements of neuroscience, lifestyle medicine, and artificial intelligence, the company has created a new modality for treating a broad range of conditions that share common root causes. The company's digital therapeutics have been validated in peer-reviewed and published clinical trials. Better is beginning to commercialize with health plans, while pursuing regulatory approval of its first prescription digital therapeutic in diabetes. The company is headquartered in San Francisco, CA, and has business operations in Boston, MA, and Nashville, TN.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicole Landberg
@Better_TX
Follow >
Better Therapeutics

Visit website